Ofirnoflast

DB21679InvestigationalSmall molecule

Ofirnoflast is a small molecule drug. The usage of the INN stem '-noflast' in the name indicates that Ofirnoflast is a inflammasome protein NLRP3 inhibitor. Ofirnoflast is under investigation in... Ofirnoflast is under investigation in clinical trial NCT07052006 (HT-6184 in Subjects With MDS).

Mechanism: Pharmacologically active on Serine/threonine-protein kinase Nek7
Curator reviewed
Formula / weight: C₂₃H₁₉F₄N₇O₂ · 501.446 g/mol (avg)

Resolves to

Compound

UNII54PY2PBN7SCAS2731294-23-6ChEMBLCHEMBL5750400

Structure

InChIKeyMJUUWYZZPRAKCW-UHFFFAOYSA-NSMILESNC1=C2C(=CN(C3CC3)C2=NC=N1)C1=CC=C(NC(=O)NC2=NOC(=C2)C2(CC2)C(F)(F)F)C(F)=C1

Targets

Q8TDX7NEK7

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Ofirnoflast, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account